Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022009121 - SARS-COV-2 AND INFLUENZA COMBINATION VACCINE

Publication Number WO/2022/009121
Publication Date 13.01.2022
International Application No. PCT/IB2021/056102
International Filing Date 07.07.2021
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61P 31/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
Applicants
  • SPICONA INC. [US]/[US]
Inventors
  • GLUCK, Reinhard
  • FAZIO, Agata
  • MONTOMOLI, Emanuele
  • BANZIGER, Kaspar
  • QUINTO, Carlos
Priority Data
2010425.307.07.2020GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 AND INFLUENZA COMBINATION VACCINE
(FR) VACCIN COMBINÉ CONTRE LE SARS-COV-2 ET LA GRIPPE
Abstract
(EN) The present invention relates to combination vaccines against both influenza and COVID-19. In particular, the invention relates to combination vaccines comprising one or more influenza virus antigen and one or more SARS-CoV-2(Coronavirus SARS-CoV-2) antigen, particularly one or more SARS-CoV-2 spike protein antigen, as well as vaccines comprising polynucleotides encoding said antigens, and such vaccines for the treatment or prevention of COVID-19 (SARS-CoV-2 infection) and influenza infection.
(FR) La présente invention concerne des vaccins combinés contre la grippe et la COVID-19. En particulier, l'invention concerne des vaccins combinés comprenant un ou plusieurs antigènes du virus de la grippe et un ou plusieurs antigènes du SARS-CoV-2 (coronavirus SARS-CoV-2), en particulier un ou plusieurs antigènes de la protéine spicule du SARS-CoV -2, ainsi que des vaccins comprenant des polynucléotides codant pour lesdits antigènes, et de tels vaccins pour le traitement ou la prévention de la COVID-19 (infection par le SARS-CoV-2) et l'infection par le virus de la grippe.
Latest bibliographic data on file with the International Bureau